CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Unhealthy sleep patterns associated with Type 2 diabetes risk in racially and economically diverse adults July 18, 2024 Employee burnout leads to significant financial losses for companies February 27, 2025 HPV vaccination reduces cervical cancer across all socioeconomic groups in England May 16, 2024
Unhealthy sleep patterns associated with Type 2 diabetes risk in racially and economically diverse adults July 18, 2024